MONA S. ABDELLATEIF^1,*, NAGLAA M. HASSAN², MAHMOUD M. KAMEL², YOMNA M. EL-MELIGUI²

Oncology Research, Vol.32, No.3, pp. 577-584, 2024, DOI:10.32604/or.2023.043026

Abstract Background: microRNA-34a (miR-34a) had been reported to have a diagnostic role in acute myeloid leukemia (AML). However, its value in the bone marrow (BM) of AML patients, in addition to its role in response to therapy is still unclear. The current study was designed to assess the diagnostic, prognostic, and predictive significance of miR-34a in the BM of AML patients. Methods: The miR-34a was assessed in BM aspirate of 82 AML patients in relation to 12 normal control subjects using qRT-PCR. The data were assessed for correlation with the relevant clinical criteria, response to therapy, disease-free survival (DFS), and overall… More >

NADIA Z. SHAABAN¹, NASHWA K. IBRAHIM², HELEN N. SAADA², FATMA H. EL-RASHIDY¹, HEBATALLAH M. SHAABAN³, NERMEEN M. ELBAKARY^2,*, AHMAD S. KODOUS^1,2,*

Oncology Research, Vol.30, No.6, pp. 269-276, 2022, DOI:10.32604/or.2022.027277

Abstract Background: MicroRNAs (miRs) are small (19–25 nucleotides), non-protein coding RNAs that regulate gene expression, and thus play essential roles in cell cycle progression. The evidence has demonstrated that the expression of several miRs is dysregulated in human cancer. Methods: The study includes 179 female patients and 58 healthy women Patients were identified as luminal A, B, Her-2/neu, and basal-like, as well as classified into I, II, and III stages. Analysis of the expression fold change of miR-21 and miR-34a with molecular markers, including the oncogene Bcl-2 (B-cell lymphoma 2) and the tumor suppressor genes BRCA1 (breast cancer susceptibility gene 1),… More >